Nautilus Biotechnology, Inc.
NAUTNasdaq
$1.74
↑ +6.1%Jul 17 close · end-of-day
Price
1Y↑ +132.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$220.3M
Enterprise Value
$124.5M
P/E
—
P/S
—
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
-23.3%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$57.1M
Free Cash Flow (TTM)
-$51.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-39.5%
ROIC
—
Debt / Equity
—
Net Cash
$95.9M
Return 1Y
+136.8%
Company profile
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington.
- CEO
- Sujal M. Patel
- Sector
- Manufacturing
- Industry
- Measuring And Control Equipment
- Employees
- 130
- Headquarters
- Washington
- Website
- nautilus.bio
Management & directors
- Patel Sujal MCEO, President, and Secretary
- Suzuki KentaroChief Marketing Officer
- Murphy Matthew B.General Counsel
Roles derived from SEC Form 4 filings.
Earnings
NAUT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.12↓ -7.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | -$15.6M | -$50.3M | -$57.9M | -$63.7M | -$70.8M | -$59.0M |
| Diluted EPS | -$0.54 | -$0.60 | -$0.46 | -$0.51 | -$0.56 | -$0.47 |
| Operating cash flow | -$14.0M | -$39.2M | -$45.8M | -$51.7M | -$59.1M | -$50.7M |
| Free cash flow | -$14.9M | -$41.5M | -$48.1M | -$54.2M | -$61.3M | -$52.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$18.0M | -$16.4M | -$17.6M | -$16.6M | -$15.0M | -$13.6M | -$13.8M | -$14.7M |
| Diluted EPS | -$0.14 | -$0.13 | -$0.14 | -$0.13 | -$0.12 | -$0.11 | -$0.11 | -$0.12 |
| Operating cash flow | -$15.5M | -$13.1M | -$14.3M | -$13.9M | -$13.3M | -$11.0M | -$12.4M | -$13.1M |
| Free cash flow | -$16.0M | -$13.8M | -$14.6M | -$14.2M | -$13.7M | -$11.5M | -$12.6M | -$13.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 5, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-02 | AH Equity Partners Bio II, L.L.C. | Sale | 4,615,974 | $2.35 | $10.8M | filing |
| 2026-06-02 | AH Equity Partners Bio II, L.L.C. | Sale | 384,026 | $2.35 | $902,461.10 | filing |
| 2026-03-04 | Patel Sujal M· CEO, President, and Secretary | Buy | 25,000 | $2.61 | $65,237.50 | filing |
| 2025-11-06 | Suzuki Kentaro· Chief Marketing Officer | Buy | 4,000 | $1.49 | $5,960.00 | filing |
| 2025-09-08 | Patel Sujal M· CEO, President, and Secretary | Buy | 83,500 | $0.68 | $57,030.50 | filing |
| 2025-09-05 | Patel Sujal M· CEO, President, and Secretary | Buy | 116,500 | $0.67 | $78,544.30 | filing |
| 2025-09-04 | Murphy Matthew B.· General Counsel | Buy | 20,000 | $0.64 | $12,858.00 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.